Literature DB >> 28551292

Clinical Outcomes of Patients with Acute Basilar Artery Occlusion in Brazil: An Observational Study.

Francisco Antunes Dias1, Frederico Fernandes Alessio-Alves2, Luis Henrique Castro-Afonso3, Pedro Telles Cougo2, Clara Monteiro Antunes Barreira2, Millene Rodrigues Camilo2, Guilherme Seizem Nakiri3, Daniel Giansante Abud3, Octavio Marques Pontes-Neto2.   

Abstract

BACKGROUND: Intravenous thrombolysis (IVT) and endovascular therapy (EVT) were proven safe and effective for anterior circulation proximal occlusions. However, the most appropriate recanalization strategy in patients with acute basilar artery occlusion (BAO) is still controversial. This study aimed to assess outcomes of patients with BAO at an academic stroke center in Brazil.
METHODS: This is a retrospective analysis of consecutive patients with BAO from a prospective stroke registry at Ribeirão Preto Medical School. Primary outcomes were mortality and favorable outcome (modified Rankin score [mRS] ≤3) at 90 days. After univariate analyses, multivariate logistic regressions were used to identify independent predictors of primary outcomes.
RESULTS: Between August 2004 and December 2015, 63 (65% male) patients with BAO and median National Institutes of Health Stroke Scale (NIHSS) score of 31 (interquartile range: 19-36) were identified. Twenty-nine (46%) patients received no acute recanalization therapy, 15 (24%) received IVT, and 19 (30%) received EVT (68% treated with stent retrievers). Twenty-four (83%) patients treated conservatively died, and only 2 (7%) achieved an mRS less than or equal to 3. Among patients treated with acute recanalization therapies, 15 (44%) died, and 9 (26.5%) had a favorable outcome. On multivariate analysis, baseline systolic blood pressure (odds ratio [OR] = .97; 95% confidence interval [CI]: .95-0.99; P = .023), posterior circulation Alberta Stroke Program Early CT score (OR = .62; 95% CI: .41-0.94; P = .026), and successful recanalization (OR = .18; 95% CI: .04-0.71; P = .015) were independent predictors of lower mortality. Baseline NIHSS (OR = 1.40; 95% CI: 1.08-1.82; P = .012), prior use of statins (OR = .003; 95% CI: .001-0.28; P = .012), and successful recanalization (OR = .05; 95% CI: .001-0.27; P = .009) were independent predictors of favorable outcome. There was no significant difference between the IVT group and the EVT group on primary outcomes.
CONCLUSIONS: BAO is associated with high morbidity and mortality in Brazil. Access to acute recanalization therapies may decrease mortality in those patients.
Copyright © 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute ischemic stroke; basilar artery occlusion; endovascular therapy; intravenous thrombolysis

Mesh:

Year:  2017        PMID: 28551292     DOI: 10.1016/j.jstrokecerebrovasdis.2017.04.043

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  3 in total

1.  Predictors of unfavorable outcome at 90 days in basilar artery occlusion patients.

Authors:  Yu-Chen Chiu; Jia-Li Yang; Wei-Chun Wang; Hung-Yu Huang; Wei-Liang Chen; Pao-Sheng Yen; Ying-Lin Tseng; Hsiu-Hsueh Chen; Sheng-Ta Tsai
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

2.  Thrombectomy for Comatose Patients with Basilar Artery Occlusion : A Multicenter Study.

Authors:  Adrien Guenego; Ludovic Lucas; Benjamin Gory; Sébastien Richard; Mathilde Aubertin; David Weisenburger-Lile; Julien Labreuche; Cyril Dargazanli; Amel Benali; Romain Bourcier; Lili Detraz; Stéphane Vannier; Maud Guillen; François Eugene; Gregory Walker; Ronda Lun; Andrew Wormsbecker; Célina Ducroux; Michel Piotin; Raphael Blanc; Arturo Consoli; Bertrand Lapergue; Robert Fahed
Journal:  Clin Neuroradiol       Date:  2021-03-11       Impact factor: 3.649

3.  Posterior circulation acute stroke prognosis early CT scores in predicting functional outcomes: A meta-analysis.

Authors:  Wei-Zhen Lu; Hui-An Lin; Chyi-Huey Bai; Sheng-Feng Lin
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.